Last reviewed 2026-04-20 · How we verify

INDIUM IN 111 SATUMOMAB PENDETIDE

FDA-approved approved Monoclonal antibody Quality 2/100

INDIUM IN 111 SATUMOMAB PENDETIDE is a drug. It is currently FDA-approved (first approved 1991).

Indium In 111 Satumomab Pendetide is a marketed radiopharmaceutical agent with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	INDIUM IN 111 SATUMOMAB PENDETIDE
Modality	Monoclonal antibody
Phase	FDA-approved
First approval	1991

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

INDIUM IN 111 SATUMOMAB PENDETIDE CI brief — competitive landscape report
INDIUM IN 111 SATUMOMAB PENDETIDE updates RSS · CI watch RSS

Frequently asked questions about INDIUM IN 111 SATUMOMAB PENDETIDE

What is INDIUM IN 111 SATUMOMAB PENDETIDE?

INDIUM IN 111 SATUMOMAB PENDETIDE is a Monoclonal antibody drug.

When was INDIUM IN 111 SATUMOMAB PENDETIDE approved?

INDIUM IN 111 SATUMOMAB PENDETIDE was first approved on 1991.

What development phase is INDIUM IN 111 SATUMOMAB PENDETIDE in?

INDIUM IN 111 SATUMOMAB PENDETIDE is FDA-approved (marketed).

Compare: INDIUM IN 111 SATUMOMAB PENDETIDE vs similar drugs
Pricing: INDIUM IN 111 SATUMOMAB PENDETIDE cost, discount & access